Form 4: Aerovate Therapeutics CEO Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Timothy Noyes, CEO of Aerovate Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On May 16, 2024, Timothy Noyes, the CEO of Aerovate Therapeutics, exercised stock options to acquire 10,000 shares of common stock at a price of $2.14 per share.
- Simultaneously, Noyes sold 8,707 shares at a weighted average price of $21.5241 and 1,293 shares at a weighted average price of $21.922.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on November 27, 2023.
- Following these transactions, Noyes directly owns 343,381 derivative securities (stock options).
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports routine transactions under a pre-arranged trading plan. There is no indication of positive or negative sentiment towards the company's prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. The use of a 10b5-1 plan suggests the transactions were pre-planned and not based on any specific non-public information.
Key Dates
| Date | Description |
|---|---|
| 2021-04-02 | Grant date of employee stock options for 493,381 shares. |
| 2022-06-04 | 25% of employee stock options vested. |
| 2023-11-27 | Date the Reporting Person adopted a Rule 10b5-1 trading plan. |
| 2024-05-16 | Date of the reported transactions: exercising options and selling shares. |
| 2024-05-17 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.